Compare Heron Therapeutics Inc (HRTX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs J M Smucker Co — how do they compare? Heron Therapeutics Inc trades at $0.34 (market cap $61.47M), while J M Smucker Co trades at $118.3 (market cap $12.54B). The key difference: J M Smucker Co is far larger — about 204× Heron Therapeutics Inc's market cap, and J M Smucker Co pays a 3.82% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SJM | |
|---|---|---|
Market Cap | $61.47M | $12.54B |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $126.35 |
52-Week Low | $0.32 | $89.53 |
Enterprise Value | $168.21M | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
SJM trades at $118.07, down 1.74% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported mixed fundamentals with strong revenue growth to $8.73B in 2025 but negative net income of -$1.23B. Recent dividend increases and positive earnings beats in Q4 2025 and Q1 2026 highlight management's confidence amid profitability challenges.
Wall Street maintains a cautiously optimistic outlook with 52% analyst buy ratings and a $125.11 consensus target, representing 6% upside. Key risks include persistent negative margins and high debt levels, while opportunities lie in cost controls and Uncrustables growth. The stock offers value at reasonable P/S and P/B multiples with dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
